Risperdal News and Research

RSS

Antidepressants are not designed for dementia, shows study

Nearly three-quarters of older adults with dementia have filled prescriptions for medicines that act on their brain and nervous system, but aren't designed for dementia, a new study shows.

19 Aug 2020

Potential inhibitors of SARS-CoV-2 identified

Now, a new study published on the preprint server bioRxiv in August 2020 reports the discovery of two inhibitors of the helicase enzyme, which is essential for viral replication and the most highly conserved non-structural coronavirus (CoV) protein.

16 Aug 2020

Alkermes reports financial results for first quarter of 2014

Alkermes plc today reported financial results for the first quarter of 2014. "During the quarter, we continued to generate positive cash flow, reflecting the strength of our commercial business and enabling us to invest in our advancing late-stage pipeline and prepare for the launch of aripiprazole lauroxil," commented James Frates, Chief Financial Officer of Alkermes.

30 Apr 2014

State highlights: State mental hospitals compared to prisons; Johnson & Johnson ruling; Va. hospitals pick new leader

Arkansas Attorney General Dustin McDaniel asked the state Supreme Court on Monday to reconsider its decision tossing out a $1.2 billion judgment against drugmaker Johnson & Johnson, saying justices did "significant harm" to the state and broke from 170 years of precedent.

9 Apr 2014

First Edition: April 8, 2014

Kaiser Health News staff writer Jay Hancock reports: "Under intense, bipartisan political pressure, the Obama administration backed down for the second year in a row on proposed payment cuts for insurance companies that offer private plans to Medicare members.

8 Apr 2014

State highlights: Ark. court reverses $1.2B Medicaid drug judgment; Fla. officials overhauling child welfare agency

The Arkansas Supreme Court reversed a $1.2 billion judgment against Johnson & Johnson on Thursday, finding that the state attorney general erred by suing under a law that applied to health care facilities, not drug companies. The judgment, one of the largest in history for a state fraud case, was imposed in 2012 after a jury concluded that Johnson & Johnson had improperly marketed and concealed the risks of Risperdal, an antipsychotic drug (Thomas, 3/2).

24 Mar 2014

First Edition: March 21, 2014

Today's early morning highlights from the major news organizations, including a new examination of Ezekiel Emanuel's book about the crafting of the health law and President Obama's latest push to boost enrollment.

21 Mar 2014

Janssen Pharmaceuticals to pay over $1.6 billion in drug misbranding case

On behalf of the U.S. Food and Drug Administration, the U.S. Department of Justice today announced a guilty plea agreement with Janssen Pharmaceuticals, Inc., of Titusville, N.J., and a $400 million criminal fine for introducing a misbranded drug, Risperdal (risperidone), into interstate commerce.

5 Nov 2013

Alkermes reports 38% of year-over-year revenue growth from key products

Alkermes plc today reported financial results for the quarter ended Sept. 30, 2013. This is the second quarter of the nine-month period ending Dec. 31, 2013, as the company transitions to reporting on a calendar year basis.

31 Oct 2013

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Janssen Pharmaceuticals, Inc. announced today a newly published, pooled analysis of the Phase III EINSTEIN trial program, showing XARELTO (rivaroxaban) is as effective as the standard of care in reducing the risk of deep vein thrombosis and pulmonary embolism in people with symptomatic DVT or PE, while reducing the incidence of major bleeding by 46 percent.

21 Sep 2013

State highlights: Ark. AG asks state Supreme Court to uphold J&J fine; N.Y. abortion measure to get separate vote

Arkansas' attorney general filed a brief Tuesday backed by his counterparts in 35 other states asking the Arkansas Supreme Court to uphold a $1.2 billion fine levied against Johnson & Johnson and a subsidiary over the marketing of the antipsychotics drug Risperdal (6/18).

20 Jun 2013

First Edition: June 19, 2013

Today's headlines include reports the development of the health law's online marketplaces is falling behind schedule.

19 Jun 2013

State roundup: Minn. officials want money for coverage expansion

Gov. Mark Dayton and his Human Services commissioner will travel to Washington, D.C., this week to lobby for federal money for MinnesotaCare. MinnesotaCare is a state-subsidized health plan that insures about 130,000 people under age 65. Dayton and Commissioner Lucinda Jesson are scheduled to meet Tuesday in Washington with Health and Human Services Secretary Kathleen Sebelius.

5 Feb 2013

Off label atypical antipsychotic use lacks safety and effectiveness in patients over 40

In older adults, antipsychotic drugs are commonly prescribed off-label for a number of disorders outside of their Food and Drug Administration (FDA)-approved indications - schizophrenia and bipolar disorder. The largest number of antipsychotic prescriptions in older adults is for behavioral disturbances associated with dementia, some of which carry FDA warnings on prescription information for these drugs.

28 Nov 2012

La. panel kills health exchange plan; Kansas enacts another abortion hurdle; Utah official resigns after medical records breach

With a decisive 8-1 vote late Tuesday evening, the Louisiana Senate Finance Committee buried a bill that would have set up a body of elected and appointed officials to craft the exchanges that are an anchor of President Barack Obama's health insurance overhaul. With the death of Senate Bill 744, Louisiana remains one of a handful of states that have refused to set up their own exchanges, with Gov. Bobby Jindal punting the job back to federal government that he accuses of taking over the American health care system

17 May 2012

Newly diagnosed schizophrenia patients continue to use oral Abilify as first-line therapy

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that analysis of U.S. longitudinal patient-level claims data reveals the use of Bristol-Myers Squibb's oral Abilify as a first-line therapy for newly diagnosed schizophrenia patients continues to grow.

10 May 2012

Risperdal News and Research

Antidepressants are not designed for dementia, shows study

Potential inhibitors of SARS-CoV-2 identified

Alkermes reports financial results for first quarter of 2014

State highlights: State mental hospitals compared to prisons; Johnson & Johnson ruling; Va. hospitals pick new leader

First Edition: April 8, 2014

State highlights: Ark. court reverses $1.2B Medicaid drug judgment; Fla. officials overhauling child welfare agency

First Edition: March 21, 2014

Janssen Pharmaceuticals to pay over $1.6 billion in drug misbranding case

Alkermes reports 38% of year-over-year revenue growth from key products

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

State highlights: Ark. AG asks state Supreme Court to uphold J&J fine; N.Y. abortion measure to get separate vote

First Edition: June 19, 2013

State roundup: Minn. officials want money for coverage expansion

Off label atypical antipsychotic use lacks safety and effectiveness in patients over 40

La. panel kills health exchange plan; Kansas enacts another abortion hurdle; Utah official resigns after medical records breach

Newly diagnosed schizophrenia patients continue to use oral Abilify as first-line therapy

Feds ask court to 'force' J&J executive to testify in lawsuit alleging kickbacks and Medicaid fraud

Johnson & Johnson fined $1.2B for hiding anti-psychotic drug dangers, deceptive marketing

First Edition: April 12, 2012

N.Y. seeking Medicaid waiver; Calif. adult services lawsuit now 'unsettled'

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News